No patients have received Casgevy, CRISPR Therapeutics and Vertex Pharmeceuticals’ recently approved sickle cell gene therapy ...

The FDA has lost no time in approving Vertex Pharma and CRISPR Therapeutics pioneering gene-editing therapy Casgevy for its second use, approving the drug for transfusion-dependent beta ...

Vertex said sickle cell patients had not yet received infusions of its gene therapy Casgevy. That’s now changed, as the ...

Vertex and CRISPR ... for their gene-editing therapy Casgevy as a treatment for the blood disorder beta thalassaemia, a few months after turning it dow Vertex Pharma has filed for FDA approval ...

The 12-month price targets, analyzed by analysts, offer insights with an average target of $508.38, a high estimate of ...

Vertex Pharmaceuticals has agreed to acquire Alpine ... The Boston-based company’s drug Casgevy, a treatment for sickle-cell ...

Casgevy is the first medicine to be licensed ... Novel ex vivo engineered cell therapies to be developed by Vertex Pharma and Arbor Biotechnologies Under this new partnership, Vertex will receive ...

Vertex Pharmaceuticals Inc. closed $45.72 below its 52-week high ($510.64), which the company achieved on August 1st.

Naz Rahman, an analyst from Maxim Group, has initiated a new Hold rating on Vertex Pharmaceuticals (VRTX ... The launch of Casgevy for SCD and TDT is acknowledged as potentially blockbuster ...

In a report released today, Brian Abrahams from RBC Capital maintained a Hold rating on Vertex Pharmaceuticals (VRTX – Research Report), ...

Vertex Pharmaceuticals Incorporated VRTX reported ... Vertex and partner CRISPR Therapeutics’ CRSP one-shot gene therapy Casgevy was approved for two blood disorders, sickle cell disease ...